Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/new-microtubule-inhibitors-in-breast-cancer-dmRg1TMPwK
References (76)
-
Chun Li, S. Wallace (2008)
Polymer-drug conjugates: recent development in clinical oncology.Advanced drug delivery reviews, 60 8
-
C. West, P. Price (2004)
Combretastatin A4 phosphate.Anti-cancer drugs, 15 3
-
X. Pivot, P. Koralewski, J. Hidalgo, A. Chan, A. Gonçalves, G. Schwartsmann, S. Assadourian, J. Lotz (2008)
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.Annals of oncology : official journal of the European Society for Medical Oncology, 19 9
-
D. Parkin, F. Bray, J. Ferlay, P. Pisani (2005)
Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 55
-
M. Shionoya, T. Jimbo, Mayumi Kitagawa, T. Soga, A. Tohgo (2003)
DJ‐927, a novel oral taxane, overcomes P‐glycoprotein‐mediated multidrug resistance in vitro and in vivoCancer Science, 94
-
E. Rankin, Duonan Yu, Jiu Jiang, Hao Shen, E. Pearce, M. Goldschmidt, David evy, T. Golovkina, C. Hunter, A. Thomas-Tikhonenko (2003)
An Essential Role of Th1 Responses and Interferon-gamma in Infection-Mediated Suppression of Neoplastic GrowthCancer Biology & Therapy, 2
-
J. Baselga, M. Campone, M. Piccart, H. Burris, H. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K. Pritchard, F. Lebrun, J. Beck, Yoshinori Ito, D. Yardley, I. Deleu, Alejandra Perez, T. Bachelot, L. Vittori, Zhi-Xia Xu, P. Mukhopadhyay, D. Lebwohl, G. Hortobagyi (2012)
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.The New England journal of medicine, 366 6
-
L. Devriese, P. Witteveen, P. Witteveen, S. Marchetti, M. Mergui-Roelvink, Larisa Reyderman, J. Wanders, A. Jenner, G. Edwards, J. Beijnen, Emile Voest, Emile Voest, J. Schellens, J. Schellens (2012)
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairmentCancer Chemotherapy and Pharmacology, 70
-
C. Villanueva, A. Vuillemin, M. Demarchi, F. Bazán, L. Chaigneau, X. Pivot (2009)
Ixabepilone: A New Active Chemotherapy in the Treatment of Breast CancerWomen's Health, 5
-
P. Fumoleau, R. Largillier, C. Clippe, V. Diéras, H. Orfeuvre, T. Lesimple, S. Culine, B. Audhuy, D. Serin, H. Curé, É. Vuillemin, J. Morère, F. Montestruc, Z. Mouri, M. Namer (2004)
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.European journal of cancer, 40 4
-
H. Rugo, M. Campone, Dino Amadori, Andrew Wardley, E. Villa, Pierfranco Conte, B. Mudenda, B. McHenry, X. Pivot (2010)
Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
S. Cisternino, F. Bourasset, Y. Archimbaud, D. Semiond, G. Sanderink, J. Scherrmann (2003)
Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and ratsBritish Journal of Pharmacology, 138
-
M. Bissery, H. Bouchard, J. Riou, P. Vrignaud, C. Combeau, J. Bourzat, A. Commerçon, F. Lavelle (2000)
Preclinical evaluation of TXD258, a new taxoid, 41
-
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, D. Forman (2011)
Global cancer statisticsCA: A Cancer Journal for Clinicians, 61
-
M. Roche, Helena Kyriakou, M. Seiden (2006)
Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative.Current opinion in investigational drugs, 7 12
-
K. Gelmon, Jean Latreille, A. Tolcher, Luc Génier, B. Fisher, Dominique Forand, S. D’Aloisio, Laurent Vernillet, Luc Daigneault, Ann Lebecq, M. Besenval, Elizabeth Eisenhauer (2000)
Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 24
-
V. Diéras, P. Viens, C. Veyret, G. Romieu, A. Awada, E. Lidbrink, H. Bonnefoi, D. Mery-mignard, F. Dalenc, H. Roché (2008)
Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label studyJournal of Clinical Oncology, 26
-
J. Treat, N. Damjanov, C. Huang, S. Zrada, A. Rahman (2001)
Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel.Oncology, 15 5 Suppl 7
-
P. Fumoleau, H. Cortés-Funes, A. Taleb, S. Chan, M. Campone, J. Pouget, M. Tubiana‐Hulin, C. Slabber, Isabelle Caroff-Paraïso, A. Alberts, F. Ayed (2009)
Phase 2 Study of Single-Agent IV Vinflunine as Third-Line Treatment of Metastatic Breast Cancer After Failure of Anthracycline-/Taxane-Based ChemotherapyAmerican Journal of Clinical Oncology, 32
-
A. Kamath, Ming Chang, F. Lee, Yueping Zhang, P. Marathe (2005)
Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analogCancer Chemotherapy and Pharmacology, 56
-
R. Oostendorp, P. Witteveen, B. Schwartz, L. Vainchtein, M. Schot, A. Nol, H. Rosing, J. Beijnen, E. Voest, J. Schellens (2010)
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumorsInvestigational New Drugs, 28
-
V. Diéras, S. Limentani, G. Romieu, M. Tubiana‐Hulin, A. Lortholary, P. Kaufman, V. Girre, M. Besenval, V. Valero (2008)
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.Annals of oncology : official journal of the European Society for Medical Oncology, 19 7
-
E. Thomas, H. Gómez, Rubi Li, H. Chung, L. Fein, Valorie Chan, J. Jassem, X. Pivot, J. Klimovsky, F. Mendoza, Bing-he Xu, M. Campone, G. Lerzo, R. Peck, P. Mukhopadhyay, L. Vahdat, H. Roché (2007)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 33
-
N. Lin, L. Parker, S. Come, H. Burstein, Margaret Haldoupis, N. Ryabin, R. Gelman, E. Winer, L. Shulman (2007)
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactionsInvestigational New Drugs, 25
-
A Awada, IN Bondarenko, O Tarasova (2010)
Results of the first randomized phase II study of Cationic Liposomal Paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)Ann Oncol, 21
-
T. Synold, R. Morgan, E. Newman, H. Lenz, D. Gandara, A. Colevas, M. Lewis, J. Doroshow (2005)
A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trialJournal of Clinical Oncology, 23
-
T. Mukohara, S. Nagai, H. Mukai, Masayuki Namiki, H. Minami (2011)
Eribulin mesylate in patients with refractory cancers: a Phase I studyInvestigational New Drugs, 30
-
J. Cortés, J. O’Shaughnessy, D. Loesch, J. Blum, L. Vahdat, K. Petráková, P. Chollet, A. Manikas, V. Diéras, T. Delozier, V. Vladimirov, F. Cardoso, H. Koh, P. Bougnoux, C. Dutcus, S. Seegobin, D. Mir, N. Meneses, J. Wanders, C. Twelves (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 377
-
Gavin Thurston, John McLean, Michael Rizen, P. Baluk, A. Haskell, Thomas Murphy, Douglas Hanahan, Donald McDonald (1998)
Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.The Journal of clinical investigation, 101 7
-
R. Campbell, B. Ying, G. Kuesters, Ryan Hemphill (2009)
Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics.Journal of pharmaceutical sciences, 98 2
-
Alan Keller, R. Mennel, V. Georgoulias, J. Nabholtz, A. Erazo, A. Lluch, C. Vogel, M. Kaufmann, Gunther Minckwitz, I. Henderson, L. Mellars, L. Alland, C. Tendler (2004)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 19
-
J. Baselga, J. Cortés, Sung-Bae Kim, S. Im, R. Hegg, Y. Im, L. Roman, J. Pedrini, T. Pieńkowski, A. Knott, E. Clark, M. Benyunes, G. Ross, S. Swain (2012)
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.The New England journal of medicine, 366 2
-
L. Schwartzberg, P. Rubin, A. Patnaik, L. Itri, A. Olson, A. Seidman (2011)
P5-19-11: Tesetaxel, an Oral Taxane, as First-Line Therapy for Women with Metastatic Breast Cancer.Cancer Research, 71
-
J. Ribeiro, Ligia Macedo, G. Curigliano, Luca Fumagalli, M. Locatelli, M. Dalton, A. Quintela, J. Carvalheira, S. Manunta, L. Mazzarella, J. Brollo, A. Goldhirsch (2012)
Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?Annals of oncology : official journal of the European Society for Medical Oncology, 23 3
-
C. Barrios, Mei-Ching Liu, S. Lee, L. Vanlemmens, J. Ferrero, T. Tabei, X. Pivot, H. Iwata, K. Aogi, Roberto Lugo-Quintana, N. Harbeck, Marla Brickman, Ke Zhang, K. Kern, Miguel Martín (2010)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerBreast Cancer Research and Treatment, 121
-
F. Puglisi, G. Cardellino, C. Loreto, D. Lombardi, T. Perin, C. Puppin, C. Andreetta, S. Russo, A. Minisini, M. Mansutti, Stefano Pizzolitto, Gianna Adami, M. Dipasquale, A. Veronesi (2008)
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 19 9
-
J. Cortés, L. Vahdat, J. Blum, C. Twelves, M. Campone, H. Roché, T. Bachelot, A. Awada, R. Paridaens, A. Gonçalves, D. Shuster, J. Wanders, F. Fang, R. Gurnani, E. Richmond, Patricia Cole, S. Ashworth, M. Allison (2010)
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 25
-
C. Curtis, Sohrab Shah, S. Chin, G. Turashvili, O. Rueda, M. Dunning, D. Speed, A. Lynch, S. Samarajiwa, Yinyin Yuan, S. Gräf, G. Ha, Gholamreza Haffari, A. Bashashati, R. Russell, S. McKinney, A. Langerød, A. Green, E. Provenzano, G. Wishart, S. Pinder, P. Watson, F. Markowetz, L. Murphy, I. Ellis, A. Purushotham, A. Børresen-Dale, J. Brenton, S. Tavaré, C. Caldas, S. Aparicio (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 486
-
T. Fojo, M. Menefee (2007)
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.Annals of oncology : official journal of the European Society for Medical Oncology, 18 Suppl 5
-
P. Kaufman, A. Awada, C. Twelves, L. Yelle, E. Perez, J. Wanders, Olivo, Yi He, C. Dutcus (2012)
Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanesCancer Research, 72
-
Tatiana Okouneva, O. Azarenko, L. Wilson, B. Littlefield, M. Jordan (2008)
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMolecular Cancer Therapeutics, 7
-
(2012)
Tesetaxel: Analysis of Two Dosing Schedules (ONCE WEEKLY VS. EVERY 3 WEEKS) Using a Novel Oral Taxane -
W. Barry, A. Moreno-Aspitia, A. Lyss, C. Cirrincione, E. Mayer, M. Naughton, R. Layman, L. Carey, R. Somer, E. Perez, C. Hudis, E. Winer (2012)
CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 18_suppl
-
S. Goel, A. Mita, M. Mita, E. Rowinsky, Q. Chu, N. Wong, C. Desjardins, F. Fang, M. Jansen, D. Shuster, S. Mani, C. Takimoto (2009)
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid MalignanciesClinical Cancer Research, 15
-
P. Morrow, S. Divers, L. Provencher, S. Luoh, T. Petrella, M. Giurescu, T. Schmelter, Yao Wang, G. Hortobagyi, L. Vahdat (2010)
Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapyBreast Cancer Research and Treatment, 123
-
A. Tan, E. Rubin, D. Walton, D. Shuster, Y. Wong, F. Fang, S. Ashworth, L. Rosen (2009)
Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid TumorsClinical Cancer Research, 15
-
M. Piccart-Gebhart, T. Burzykowski, M. Buyse, G. Sledge, J. Carmichael, H. Lück, J. Mackey, J. Nabholtz, R. Paridaens, L. Biganzoli, J. Jassem, M. Bontenbal, J. Bonneterre, S. Chan, G. Basaran, P. Therasse (2008)
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 12
-
J. Bennouna, P. Fumoleau, J. Armand, Eric Raymond, M. Campone, F. Delgado, C. Puozzo, Michel Marty (2003)
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours.Annals of oncology : official journal of the European Society for Medical Oncology, 14 4
-
C. Sessa, C. Cuvier, S. Caldiera, Joshua Bauer, S. Bosch, C. Monnerat, D. Semiond, D. Pérard, A. Lebecq, M. Besenval, M. Marty (2002)
Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.Annals of oncology : official journal of the European Society for Medical Oncology, 13 7
-
R. Freedman, E. Bullitt, Lixian Sun, R. Gelman, G. Harris, J. Ligibel, I. Krop, A. Partridge, E. Eisenberg, E. Winer, N. Lin (2011)
A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.Clinical breast cancer, 11 6
-
D. Yardley, M. Mccleod, F. Schreiber, P. Murphy, Jeffrey Patton, Dana Thompson, M. Shastry, M. Rubin, M. Melnik, H. Burris, J. Hainsworth (2010)
A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast CancerCancer Investigation, 28
-
D. Dabydeen, J. Burnett, R. Bai, P. Verdier-Pinard, Sarah Hickford, G. Pettit, J. Blunt, M. Munro, R. Gussio, E. Hamel (2006)
Comparison of the Activities of the Truncated Halichondrin B Analog NSC 707389 (E7389) with Those of the Parent Compound and a Proposed Binding Site on TubulinMolecular Pharmacology, 70
-
Miguel Martín, A. Ruíz, Monserrat Muñoz, A. Balil, J. García-Mata, L. Calvo, E. Carrasco, Esther Mahillo, A. Casado, J. García-Saenz, M. Escudero, V. Guillem, C. Jara, N. Ribelles, F. Salas, C. Soto, F. Morales-Vásquez, C. Rodríguez, E. Adrover, J. Mel (2007)
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.The Lancet. Oncology, 8 3
-
X. Pivot, Rubi Li, E. Thomas, H. Chung, L. Fein, Valorie Chan, J. Jassem, F. Mendoza, Pralay Mukhopadyay, H. Roché (2009)
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.European journal of cancer, 45 17
-
E. Perez, G. Lerzo, X. Pivot, E. Thomas, L. Vahdat, L. Bosserman, P. Viens, C. Cai, B. Mullaney, R. Peck, G. Hortobagyi (2007)
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 23
-
Jennifer Smith, L. Wilson, O. Azarenko, Xiaojie Zhu, B. Lewis, B. Littlefield, M. Jordan (2010)
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability.Biochemistry, 49 6
-
P. Sabbatini, C. Aghajanian, D. Dizon, S. Anderson, J. Dupont, John Brown, W. Peters, A. Jacobs, A. Mehdi, S. Rivkin, A. Eisenfeld, D. Spriggs (2004)
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 22
-
Takayasu Kurata, Yasuhiro Shimada, T. Tamura, N. Yamamoto, I. Hyodo, Toshiaki Saeki, Shigemitsu Takashima, Keiichi Fujiwara, Hideyuki Wakasugi, M. Kashimura (2000)
Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 17
-
J. Blum, M. Savin, G. Edelman, J. Pippen, N. Robert, B. Geister, R. Kirby, A. Clawson, J. O’Shaughnessy (2007)
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.Clinical breast cancer, 7 11
-
R. Paridaens, H. Wildiers, F. Dalenc, O. Rixe, V. Cadic, M. Pinel, H. Roché (2007)
Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancerJournal of Clinical Oncology, 25
-
K. Aogi, H. Iwata, N. Masuda, H. Mukai, Masayuki Yoshida, Y. Rai, K. Taguchi, Y. Sasaki, S. Takashima (2012)
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 23 6
-
J. Rossari, O. Metzger-Filho, M. Paesmans, K. Saini, A. Gennari, E. Azambuja, M. Piccart-Gebhart (2012)
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available EvidenceJournal of Oncology, 2012
-
Fatima Cardoso, A. Costa, Larry Norton, D. Cameron, T. Cufer, Lesley Fallowfield, P. Francis, J. Gligorov, S. Kyriakides, Nan Lin, O. Pagani, E. Senkus, Christoph Thomssen, M. Aapro, J. Bergh, A. Leo, N. Saghir, Patricia Ganz, K. Gelmon, A. Goldhirsch, Nadia Harbeck, N. Houssami, C. Hudis, Bella Kaufman, M. Leadbeater, M. Mayer, Alan Rodger, H. Rugo, V. Sacchini, G. Sledge, L. Veer, Giuseppe Viale, I. Krop, E. Winer (2012)
1st International consensus guidelines for advanced breast cancer (ABC 1).Breast, 21 3
-
JE Frampton, MD Moen (2010)
VinflunineDrugs, 70
-
Niamh O’Boyle, M. Carr, L. Greene, Orla Bergin, Seema Nathwani, T. McCabe, D. Lloyd, D. Zisterer, M. Meegan (2010)
Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.Journal of medicinal chemistry, 53 24
-
S. Fogh, M. Machtay, M. Werner-Wasik, W. Curran, R. Bonanni, R. Axelrod, D. Andrews, A. Dicker (2010)
Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies.International journal of radiation oncology, biology, physics, 77 4
-
J. Bellmunt, C. Théodore, T. Demkov, B. Komyakov, L. Sengeløv, G. Daugaard, A. Caty, J. Carles, A. Jagiełło-Gruszfeld, O. Karyakin, F. Delgado, P. Hurteloup, E. Winquist, N. Morsli, Y. Salhi, S. Culine, H. Maase (2009)
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 27
-
A. Lockhart, R. Tirona, R. Kim (2003)
Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy.Molecular cancer therapeutics, 2 7
-
Kaoru Tanaka, T. Kurata, Y. Fujisaka, H. Kawakami, H. Hayashi, T. Cousin, W. Okamoto, T. Kudoh, T. Satoh, K. Nakagawa (2012)
Pharmacokinetics (PK) and Safety of Tesetaxel, a Novel Oral Taxane, in Japanese Patients (PTS) with Advanced Solid TumorsAnnals of Oncology, 23
-
L. Vahdat, B. Pruitt, C. Fabian, R. Rivera, David Smith, E. Tan-chiu, Jonathan Wright, A. Tan, N. Dacosta, E. Chuang, John Smith, J. O’Shaughnessy, D. Shuster, N. Meneses, K. Chandrawansa, F. Fang, Patricia Cole, S. Ashworth, J. Blum (2009)
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 18
-
Barbara McGrogan, B. Gilmartin, D. Carney, A. McCann (2008)
Taxanes, microtubules and chemoresistant breast cancer.Biochimica et biophysica acta, 1785 2
-
J. Sparano, E. Vrdoljak, O. Rixe, Bing-he Xu, A. Manikhas, C. Medina, Susanne Costa, J. Ro, G. Rubio, M. Róndinón, G. Manga, R. Peck, V. Poulart, P. Conte (2010)
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 20
-
S. Carrick, Sharon Parker, C. Thornton, D. Ghersi, J. Simes, N. Wilcken (2009)
Single agent versus combination chemotherapy for metastatic breast cancer.The Cochrane database of systematic reviews, 2
-
C. Villanueva, A. Awada, M. Campone, J. Machiels, T. Besse, E. Magherini, F. Dubin, D. Semiond, X. Pivot (2011)
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.European journal of cancer, 47 7
-
X. Pivot, L. Asmar, AU Buzdar, V. Valero, G. Hortobagyi (2000)
A unified definition of clinical anthracycline resistance breast cancerBritish Journal of Cancer, 82
-
M. Campone, N. Isambert, E. Bourbouloux, H. Roché, J. Bonneterre, G. Milano, P. Fumoleau (2012)
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanesCancer Chemotherapy and Pharmacology, 69
- Publisher
- Springer Journals
- Copyright
- Copyright © 2013 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-012-0101-9
- Publisher site
- See Article on Publisher Site
Abstract
Chemotherapy is still the main basis of treatment of metastatic breast cancer. Antimicrotubule agents regulating polymerization and depolymerization seem to be involved in a crucial physiopathogenic pathway controlling tumor growth. Such agents as paclitaxel and docetaxel have high activity and a survival benefit as first-line treatment for metastatic cancer, but several mechanisms of acquired resistance lead to refractory disease. Finding new active chemotherapeutic agents able to avoid such chemoresistance is a challenge. In this paper we review of the current state of development of new microtubule inhibitors.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Jan 19, 2013